- Home
- NERV vs PLX Comparison
NERV vs PLX Comparison
Compare NERV & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NERV | PLX |
|---|---|---|
| Founded | 2007 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.4M | 182.9M |
| IPO Year | 2014 | 1996 |
Fundamental Metrics
Financial Performance| Metric | NERV | PLX |
|---|---|---|
| Price | $3.36 | $2.70 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $10.33 | N/A |
| AVG Volume (30 Days) | 116.0K | ★ 701.9K |
| Earning Date | 11-04-2026 | 08-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | $41,175,600.00 | ★ $52,744,000.00 |
| Revenue This Year | N/A | $55.77 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $10.04 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.24 | $1.60 |
| 52 Week High | $12.46 | $3.19 |
Technical Indicators
Market Signals| Indicator | NERV | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 35.01 | 54.55 |
| Support Level | N/A | $2.59 |
| Resistance Level | $4.73 | $2.75 |
| Average True Range (ATR) | 0.24 | 0.09 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 23.94 | 46.09 |
Price Performance
Historical ComparisonAbout NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.